Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$115.81M-519%-$20.6M+67.7%-$15.62M+74.7%-$10.42M+84.1%$27.61M+140%
$22.9K-88.6%$78.9K-59.2%$124.9K-34.4%$166K-11.5%$200.3K+10.7%
$10.39M+16.3%$9.87M-8.9%$9.34M-22.8%$9.18M-27.1%$8.93M-30.3%
-$107.78M-108%-$97.43M-63.6%-$95.25M-75.9%-$95.56M-89.6%-$51.76M+10.8%
$926K-71.0%$1.47M-56.1%
$95.34M
$173.73M
-$107.78M-102%-$97.99M-60.1%-$95.99M-70.1%-$96.49M-80.0%-$53.23M+13.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Whitehawk Therapeutics, Inc. Common Stock generate?
Whitehawk Therapeutics, Inc. Common Stock (WHWK) generated -$107.8M in operating cash flow over the trailing twelve months.
What is Whitehawk Therapeutics, Inc. Common Stock's free cash flow?
After $738.0K of capital expenditures, Whitehawk Therapeutics, Inc. Common Stock's free cash flow was -$107.8M over the trailing twelve months, down 102.5% year over year.
Where does Whitehawk Therapeutics, Inc. Common Stock's cash flow data come from?
Every line is extracted from Whitehawk Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.